Published on
September 17, 2020

Former Senior Leader of Apotex Joins Nova Mentis Life Science Board and is Named COO

VANCOUVER, BC, Sept. 17, 2020 /CNW/ - Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCPK: LIBFF) ("NOVA" or the "Company") is pleased to announce the appointment of Ms. Jacqueline McConnell to its Board of Directors and as Chief Operating Officer ("COO").

Jacqueline McConnell has over twenty years of experience working for Apotex Inc., one of Canada's largest pharmaceutical companies. She provides critical business strategy input at a senior leadership level to support an organization's ability to achieve local and global growth and corporate sustainability. Ms. McConnell has proven experience developing and implementing programs and systems. Her key contributions include building and leading numerous successful teams to support efficient management of capital and operating activity across budget management, scheduling, quality, safety, and regulatory compliance.

Ms. McConnell's most recent accomplishment was to provide direct leadership and operational guidance to support a Canadian cannabis company to successfully achieve Health Canada and European (EU GMP) licensing status.

Effective immediately in her new role as COO, Ms. McConnell will assume responsibility for, among other things, managing the integration and acting as a liaison to NOVA's business segments, such as psilocybin-focused Nova Mentis Biotech Corp. and the cannabis business investments of NOVA. Further, in utilizing her background in the biotechnology and pharmaceutical industries, she will spearhead corporate development efforts and new business initiatives within this realm.

"We are thrilled to welcome a person of Jacquie's caliber to the NOVA team," stated Will Rascan, President and CEO. "Her expertise will be highly valuable as we continue advancing our corporate mandate in the health and wellness sector."

Concurrent with the appointment of Ms. McConnell to the Board of Directors, Dr. Aylia Mohammadi has stepped down from the Board in order to focus her ongoing efforts as Chief Scientific Officer in charge of the pre-clinical and planned clinical trials of Nova Mentis Biotech Corp. Per the Company's press release of August 31, 2020, NOVA has signed a master service agreement with Physiogenex, a leading preclinical contract research organization for metabolic disorders. Under the terms of the agreement, Nova Mentis Biotech shall contract Physiogenex to conduct the first of two planned preclinical studies that will focus on determining the effect of a range of psilocybin doses on different inflammation markers in order to determine the effective dose to proceed with the planned metabolic study.

Further, the Company has granted an aggregate of 2,500,000 incentive stock options ("the Options") to members of its Board, management team and consultants of the Company. The Options are exercisable for a period of two years from the date of grant at a price $0.20 per share. The Options have been granted under and are governed by the terms of the Company's incentive stock option plan.

About Nova Mentis Life Science Corp.

Nova Mentis Life Science Corp. (formerly Liberty Leaf Holdings Ltd.) is a Canadian-based, public company whose focus is to build and support a diversified portfolio of health and wellness businesses. Key holdings include its wholly-owned subsidiary, Nova Mentis Biotech Corp., a R&D driven company focused on exploring the anti-inflammatory effects of psilocybin in underexplored metabolic indications such as obesity and diabetes – Just Kush Enterprises, an Okanagan BC based, Health Canada Standard Licensed facility focused on the cultivation of premium, small batchKush dominant cultivars.

On Behalf of the Board

Will Rascan, President & CEO
Nova Mentis Life Science Corp.

Phone: 778-819-0244
Toll Free: 1-833-542-5323

Twitter: @novamentislsc
Instagram: @novamentislsc
Facebook: @novamentislsc

Neither the Canadian Securities Exchange nor its Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.

This news release contains statements that constitute "forward-looking statements." Such forward looking statements involve known and unknown risks, uncertainties and other factors that may cause Nova Mentis Life Science's actual results, performance or achievements, or developments in the industry to differ materially from the anticipated results, performance or achievements expressed or implied by such forward-looking statements. Forward looking statements are statements that are not historical facts and are generally, but not always, identified by the words "expects," "plans," "anticipates," "believes," "intends," "estimates," "projects," "potential" and similar expressions, or that events or conditions "will," "would," "may," "could" or "should" occur.

SOURCE Nova Mentis Life Science Corp.

For further information: on the Company, please visit or email